Qingkailing Injection Versus Puerarin Injection on Withdrawal Rate of Corticosteroids in Patients With Active Rheumatoid Arthritis

The Effect of Qingkailing Injection on Corticosteroids Withdrawal Rate in Patients With Active Rheumatoid Arthritis

The purpose of this study is to evaluate the effect of Qingkailing injection versus Puerarin injection on withdrawal rate of corticosteroids in patients with active rheumatoid arthritis.

Inclusion Criteria:

• with active RA
• without taking any other medication for the treatment of active RA in at least 4 last weeks
• aged from 18 to 75 years
• without conflict to the written, informed consent signed prior to the enrollment.

Exclusion Criteria:

• being included in other clinical trial within the last 4 weeks
• with abnormal liver or kidney function (more than 1 time above the high normal)
• with serious cardiovascular disease
• with hematologic disease
• being in pregnancy, lactation period or under a pregnancy plan
• with severe gastrointestinal disease
• with contraindication or being allergic to the test drugs
• being under the treatment of drugs within 1 previous week, that might affect the results of the trial, such as non-steroidal anti-inflammatory drugs, steroidal anti-inflammatory drugs, immunosuppressants, anti-ulcer drugs
• being not compatible for the trial medication, or other circumstances at the discretion of investigators
• without legal capacity or only with limited legal capacity.